Ciphergen and Quest to Develop Arterial Disease Dx | GenomeWeb
NEW YORK (GenomeWeb News) — Ciphergen and Quest Diagnostics plan to jointly develop a blood-based test for the detection of peripheral artery disease.
 
The deal is the second of a three-part alliance the firms formed last year in which Quest will use Ciphergen’s SELDI-based ProteinChip technology to create the test. The first incarnation resulted in a test that triages ovarian cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.